Effects of estrogens and hormone replacement therapy on breast cancer risk and on efficacy of breast cancer therapies (Q34034055)

30 July 2017

1 reference

title

Effects of estrogens and hormone replacement therapy on breast cancer risk and on efficacy of breast cancer therapies (English)

1 reference

Hormone Replacement Therapy

30 July 2017

1 reference

1 reference

1 reference

Verheul HA

1

1 reference

30 July 2017

Coelingh-Bennink HJ

2

1 reference

30 July 2017

Kenemans P

3

1 reference

30 July 2017

Atsma WJ

4

1 reference

30 July 2017

Burger CW

5

1 reference

30 July 2017

Eden JA

6

1 reference

30 July 2017

Hammar M

7

1 reference

30 July 2017

Marsden J

8

1 reference

30 July 2017

Purdie DW

9

1 reference

30 July 2017

language of work or name

1 reference

1 July 2000

1 reference

30 July 2017

1 reference

30 July 2017

36

1 reference

30 July 2017

1

1 reference

30 July 2017

1-17

1 reference

Sex steroids and malignancies

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Estrogen use and cancer incidence: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Effects of progestagens and Org OD14 in in vitro and in vivo tumor models

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Both estradiol and tamoxifen decrease proliferation and invasiveness of cancer cells transfected with a mutated estrogen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Estrogen receptor mediated inhibition of cancer cell invasion and motility: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Hormone replacement therapy in breast cancer survivors: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Estrogen replacement therapy for the breast cancer survivor: a reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Hormone replacement therapy and breast cancer morbidity, mortality and recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Hormone replacement therapy and breast cancer. A review of current knowledge

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Hormone replacement therapy in women with breast cancer. Do the risks outweigh the benefits?

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Estrogen replacement therapy in women with prior diagnosis and treatment for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

A prospective study of endogenous estrogens and breast cancer in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Serum sex hormone levels after menopause and subsequent breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Hysterectomy, oophorectomy in premenopause, and risk of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Hormonal therapy of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Transient Increase in the Risk of Breast Cancer after Giving Birth

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Influence of prior and subsequent pregnancy on breast cancer prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Effect of pregnancy on prognosis for young women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

The etiopathogenesis of breast cancer prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Oral contraceptive use has no adverse effect on the prognosis of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Oral contraceptives and breast cancer: final report of an epidemiological study

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Estrogen Replacement Therapy II: A Prospective Study in the Relationship to Carcinoma and Cardiovascular and Metabolic Problems

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Hormone replacement therapy and high S phase in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Estrogen replacement therapy and breast cancer: analysis of age of onset and tumor characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Estrogen replacement therapy in women with a history of proliferative breast disease

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Reduced mortality associated with long-term postmenopausal estrogen therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Postmenopausal hormone therapy and mortality.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Estrogen Replacement Therapy and Breast Cancer Survival in a Large Screening Study

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy--long-term follow-up of a Swedish cohort.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Cause-specific mortality in women receiving hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Decreased mortality in users of estrogen replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Postmenopausal estrogen use and mortality. Results from a prospective study in a defined, homogeneous community

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Hormone replacement therapy and tumour grade in breast cancer: prospective study in screening unit

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Prognostic characteristics in breast cancers after hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Hormone replacement therapy and biological aggressiveness of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Does estrogen replacement therapy reduce the risk of fatal breast cancer in postmenopausal women?

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Breast carcinoma developing in patients on hormone replacement therapy: a histological and immunohistological study

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Hormone replacement therapy in women treated for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Hormone replacement therapy in previously treated breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Hormone replacement therapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Hormone replacement after breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Hormone replacement therapy after breast cancer: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

A cohort study of hormone replacement therapy given to women previously treated for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Estrogen replacement therapy in breast cancer survivors

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

A case-control study of hormone replacement therapy after primary surgical breast cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Estrogen replacement therapy withdrawal and regression of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Hormone replacement therapy and breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Progestins and breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Management of Menopausal Symptoms in Breast Cancer Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

The effect of adjuvant therapy with or without tamoxifen on the endocrine function of patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2800%2900150-X

7 January 2021

10.1016/S0378-5122(00)00150-X

Identifiers

DOI

1 reference

30 July 2017

1 reference